Current Status of Xenotransplantation and Prospects for Clinical Application

Coagulation is occurring continuously within the blood stream, but is normally restrained by a network of inhibitory pathways involving endothelial proteins such as thrombomodulin and tissue factor pathway inhibitor (TFPI) (Panel A). Increased coagulation is normally initiated when endothelium retracts or becomes “activated” by injury, in part because von Willebrand factor (vWF) is expressed and tissue factor (TF) is liberated into the circulation. The coagulation cascade then becomes amplified by the factors shown (VIIa/TF complex, IXa and Xa) which in turn activate thrombin. Thrombin amplifies the clotting cascade by a) activating XIa (not shown), b) activating platelets, c) cleaving fibrinogen into fibrin monomers that form the primary clot matrix, and d) activating factor XIIIa (not shown), which cross-links fibrin monomers into an insoluble clot.TFPI and thrombomodulin normally inhibit coagulation on healthy endothelium, while soluble antithrombins inhibit thrombin by forming a complex with its active site.Porcine EC activation – whether by xenoantibodies, complement, or other factors – results in loss of natural anticoagulant proteins (TFPI, thrombomodulin) and acquisition of a procoagulant phenotype (Panel B). In addition functional incompatibilities in the coagulation system between pigs and humans cause both inappropriate or accelerated thrombin formation and inefficient restraint of clot activation. Our current hypothesis is that xenografts succumb to an otherwise insignificant humoral or cellular immune response which amplifies endothelial injury and intravascular thrombosis, and becomes manifest as TM.Blue arrows designate cascade amplification steps, while red lines identify loci of inhibition. The relative intensity of clot formation, the net product of coagulation pathway enzyme effects, is symbolized by arrow weight at the thrombin and fibrin steps. Pathways where pig endothelial proteins inefficiently dampen coagulation are indicated with hatchmarked red lines in Panel B. For simplicity, only the activated clotting factor intermediaries and key points at which regulation occurs are shown.
Current Status of Xenotransplantation and Prospects for Clinical Application

Publication

Current Status of Xenotransplantation and Prospects for Clinical Application. () Richard N. Pierson, et al. Xenotransplantation. ;16(5):263-280. Figure: F5.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates vWF,XII VWF ncbigene_symbol VWF 7450
Homo sapiens Primates APC APC ncbigene_symbol APC 324
Homo sapiens Primates APC APC ncbigene_synonym PROC 5624
Homo sapiens Primates Fibrinogen FIBRINOGEN famplex_relations FGA 2243
Homo sapiens Primates Fibrinogen FIBRINOGEN famplex_relations FGB 2244
Homo sapiens Primates Fibrinogen FIBRINOGEN famplex_relations FGG 2266
Homo sapiens Primates TF TF ncbigene_symbol TF 7018
Homo sapiens Primates TFPI TFPI ncbigene_symbol TFPI 7035

Chemical mentions

Word Match MeSH Name ChEBI

Disease mentions

Word Match MeSH Name DOID